BiotechTube

GB1211 + Placebo

Phase 1/2UNKNOWN
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatic Impairment

Conditions

Hepatic Impairment

Trial Timeline

Sep 9, 2021 → Jul 4, 2023

NCT ID
NCT05009680

About GB1211 + Placebo

GB1211 + Placebo is a phase 1/2 stage product being developed by Comac Medical for Hepatic Impairment. The current trial status is unknown. This product is registered under clinical trial identifier NCT05009680. Target conditions include Hepatic Impairment.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05009680Phase 1/2UNKNOWN

Competing Products

20 competing products in Hepatic Impairment

See all competitors
ProductCompanyStageHype Score
ITF2357BiotrialPhase 1
25
ACT-541468 25 mg + ACT-541468 25 mg (or 10 mg depending on interim results)IdorsiaPhase 1
28
OlomorasibEli LillyPhase 1
33
SimufilamCassava SciencesPhase 1
25
cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
77
exatecan mesylateDaiichi SankyoPhase 2
52
DS-3201bDaiichi SankyoPhase 1
33
QuizartinibDaiichi SankyoPhase 1
33
QuizartinibDaiichi SankyoPhase 1
33
PexidartinibDaiichi SankyoPhase 1
33
Tivantinib + Tivantinib + Tivantinib + TivantinibDaiichi SankyoPhase 1
33
BocidelparAstellas PharmaPhase 1
33
fezolinetantAstellas PharmaPhase 1
33
enzalutamideAstellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
ASP2215Astellas PharmaPhase 1
33
BPN14770ShionogiPhase 1
33
S-217622ShionogiPhase 1
33
LemborexantEisaiPhase 1
33
LenvatinibEisaiPhase 1
33

Other Products from Comac Medical

VaccinePhase 3
69
CHF6467 activePhase 1/2
33
Influenza vaccine, split inactivatedPhase 1
25